Among the TCGA patients, the pattern predicts survival better than and independent of the existing pathology laboratory tests, i.e., for MGMT promoter methylation and IDH1 mutation, as well as better than TERT gene expression, the most recent indicator of survival to have advanced to GBM standard of care. This evidence concerns the gene MGMT and glioblastoma.